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Background
Juvenile idiopathic arthritis (JIA) is the main cause of
chronic arthritis in children who may continue to have
active disease in adulthood. In Europe JIA patients resis-
tant to traditional therapy started to receive treatment
with biological drug Etanercept (ETN) in 2000. In Latvia
ETN therapy was started in 2004.
Aim
To evaluate the efficacy and safety of ETN therapy in
the traditional treatment resistant JIA patients.
Methods
The study included data from out-patient medical
record on 69 JIA patients (45 children, 24 adults) who
received ETN therapy during 2004 till 2010. Treatment
efficacy was assessed using the ACR (American College
of Rheumatology) Pedi 30, 50 and 70 response. Therapy
was evaluated after 3, 6, 12 and 24 months (mo) of ETN
treatment. Safety was assessed by recording ETN
adverse events (AE). Statistical data analysis was made
using Friedman, Kolmogorov-Smirnov and Pearson’s
chi-square tests.
Results
Enrolled JIA patients were 4 to 23 years old. 65 patients
(94.2%) had the sero-negative polyarthritis, 2 (2.9%) had
seropositive polyarthritis and 2 (2.9%) systemic onset
JIA. The mean disease duration before ETN therapy was
4.34 years (SD 2.50) and average ETN therapy duration
was 2 years for children and 2,88 years for adults. After
3 mo of ETN treatment 70% of patients reached ACR
Pedi 30 response, ACR Pedi 50 and ACR Pedi 70 were
reached in 20% and 10%, respectively. Effficacy
continued to improve and after 12 mo of ETN therapy
ACR Pedi 30 and 50 responses were achieved in 100%
of patients and ACR Pedi 70 response was reached in
85.7%. Significant ACR Pedi improvement observed at
the end of the first year of ETN therapy, compared to 3
and 6 mo of treatment (p = 0.002).
Etanercept side effects were detected in 12 of 69
(17.4%) patients of whom 4.35% were children. They
had mild AE - upper respiratory tract infections and
uncomplicated herpes zoster infection. In adults AE
observed in 13.05% cases – mild upper respiratory tract
infections, headache, chronic uveitis relapse, infectious
mononucleosis syndrome, and one opportunistic infec-
tion – tuberculosis.
Conclusion
1. Etanercept is an effective therapy for traditional treat-
ment resistant JIA patients. 2. Etanercept treatment effi-
cacy gradually increased between 3 and 6 mo of therapy,
reaching a maximum effect at the end of the first year of
treatment. 3. Treatment with Etanercept in childern was
safe, but in adults one JIA patient was diagnosed with
opportunistic infection - tuberculosis.
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